For research use only. Not for therapeutic Use.
KRAS G12C inhibitor 14 is a potent KRAS G12C inhibitor extracted from patent WO2019110751A1, compound 17, has an IC50 of 18 nM[1].
| Catalog Number | I018116 |
| CAS Number | 2349393-95-7 |
| Synonyms | (7R)-16-chloro-14-fluoro-15-(2-fluoro-6-hydroxyphenyl)-9-methyl-5-prop-2-enoyl-2,5,9,12-tetrazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),11,13,15,17-pentaen-8-one |
| Molecular Formula | C24H19ClF2N4O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C24H19ClF2N4O3/c1-3-18(33)30-7-8-31-16(11-30)24(34)29(2)15-10-28-22-12(23(15)31)9-13(25)19(21(22)27)20-14(26)5-4-6-17(20)32/h3-6,9-10,16,32H,1,7-8,11H2,2H3/t16-/m1/s1 |
| InChIKey | NZIBTXKFKUORFB-MRXNPFEDSA-N |
| SMILES | CN1C2=C(C3=CC(=C(C(=C3N=C2)F)C4=C(C=CC=C4F)O)Cl)N5CCN(CC5C1=O)C(=O)C=C |
| Reference | [1]. Jason Grant Kettle, et al. Tetracyclic compounds as inhibitors of g12c mutant ras protein, for use as anti-cancer agents. WO2019110751A1. |
